A Randomized, Subject- and Investigator-blinded, Placebo Controlled, Multi-center, Multiple Dose Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Moderate to Severe Asthma
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs CJM 112 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 14 Oct 2019 This trial has been completed in Germany, according to according to European Clinical Trials Database record.
- 07 Aug 2019 This trial was completed in Denmark, Slovakia and Belgium (End Date: 8 jul 2019), according to European Clinical Trials Database record.
- 17 Dec 2018 Planned End Date changed from 26 Sep 2019 to 5 Jul 2019.